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S U M M A R Y
Objectives: Serum alanine aminotransferase (ALT) is a controversial marker for disease monitoring in
hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. The aim of this study was to
determine the ﬁbrosis stage and histological activity index (HAI) in HBeAg-negative CHB patients with
persistently normal ALT (PNALT) and high serum HBV DNA (2000 IU/ml) and to investigate clinical risk
factors for the requirement of treatment through the examination of liver biopsy specimens.
Methods: HBeAg-negative CHB patients with PNALT (40 IU/l) and high serum HBV DNA (2000 IU/ml)
were included. HBV ﬁbrosis stage and HAI were scored according to the Ishak system. Multivariate logistic
regression analysis was used to estimate the independent risk factors for ﬁbrosis stage 2 and/or HAI 6.
Receiver operating characteristic curve analysis was used to determine an optimal age cut-off for liver biopsy.
Results: A total 120 patients were enrolled. These patients had a mean HBV DNA level of
123 680  494 500 IU/ml; the HBV DNA load was 2000–20 000 IU/ml in 68 patients (56.6%) and
20 000 IU/ml in 52 (43.4%). Eighteen patients (15%) had moderate-to-severe histological activity (HAI 6).
Forty-three patients (35.9%) had a ﬁbrosis stage 2. Forty-eight patients (40%) had a ﬁbrosis stage 2 and/or
HAI 6. On multivariate logistic regression analysis, independent variables associated with ﬁbrosis stage 2
and/or HAI 6 included age and HBV DNA viral load. Patients with HBV DNA 2000–20 000 IU/ml were more
likely to require treatment compared to those with a viral load 20 000 IU/ml. The optimal age cut-off to
predict ﬁbrosis stage 2 and/or HAI 6 was 46 years.
Conclusions: Signiﬁcant liver damage was detected in 40% of CHB patients with PNALT and high HBV
DNA upon biopsy. Age and HBV DNA viral load were independent predictors of signiﬁcant liver damage.
A biopsy to determine the degree of liver damage is advisable for CHB patients older than 46 years.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis B virus (HBV) infection remains an important public
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).worldwide.1 Chronic hepatitis B (CHB) has a wide clinical
spectrum, ranging from asymptomatic carrier status to cirrhosis
and hepatocellular carcinoma.2,3 Proper management of the
disease is important to prevent mortality by reducing HBV-related
complications.
The predominant type of CHB infection is hepatitis B e antigen
(HBeAg)-negative. This develops after the loss of HBeAg and can
subsequently remain in a low/non-replicative phase (inactive
chronic HBV carrier status) or progress to an active phase.4,5 Theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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without treatment can be sufﬁcient for HBV carriers; however,
HBeAg-negative CHB infections require treatment.
HBeAg-negative CHB is generally differentiated from the
inactive carrier state by serial measurement of serum alanine
aminotransferase (ALT) and HBV DNA levels. Positivity for
hepatitis B surface antigen (HBsAg), negative HBeAg, and elevated
ALT and serum HBV DNA levels are diagnostic of HBeAg-negative
CHB.6 Serum levels of ALT, an enzyme released by hepatocytes
during liver injury, usually reﬂect the degree of liver damage;
however, not every HBeAg-negative CHB-infected patient exhibits
elevated ALT. HBV DNA viral load and ALT levels can ﬂuctuate in
cases of HBeAg-negative CHB infection. A single measurement of
ALT or HBV DNA viral load is insufﬁcient to determine the current
phase of the disease. A proportion of HBeAg-negative CHB patients
can have persistently normal ALT (PNALT) levels for an extended
period.7
The European Association for the Study of the Liver (EASL)
deﬁne PNALT as an ALT below 40 IU/l when checked every 3–4
months in a single year.8
According to the latest EASL guidelines, HBeAg-negative CHB
patients with PNALT and HBV DNA levels between 2000 and
20 000 IU/ml, and who have no evidence of liver disease, do not
require immediate liver biopsy or treatment. However, it is
recommended that they receive careful follow-up, with ALT
assessments every 3 months, as well as HBV DNA load measure-
ments every 6–12 months, for at least 3 years.8
However, there have been reports of histological injury in
patients with PNALT. Furthermore, more recent studies have
shown liver damage in CHB patients with PNALT who have viral
loads above 2000 IU/ml.9,10 Liver biopsy can be used to assess the
severity of necrosis and inﬂammation in addition to ﬁbrosis, and
can rule out other causes of liver disease; hence, biopsy is regarded
as the best method to assess the severity of inﬂammatory activity
and ﬁbrosis.7
It was hypothesized that a signiﬁcant proportion of HBeAg-
negative HBV-infected patients with high HBV DNA levels may
have signiﬁcant histological liver abnormalities despite PNALT.
This prospective study was therefore performed to determine the
ﬁbrotic stage and histological activity index (HAI) in HBeAg-
negative CHB patients with PNALT and high serum HBV DNA
(2000 IU/ml) viral loads. The clinical risk factors associated with
signiﬁcant histological abnormalities in liver biopsy specimens
were also investigated.
2. Methods
2.1. Study design and setting
The study was designed as a single-center, prospective study in
the Gastroenterohepatology Department of Istanbul Faculty of
Medicine, Istanbul University. The study protocols abided by the
ethical guidelines as stated in the 1975 Declaration of Helsinki and
were approved by the local institutional review board. Written
informed consent for participation in the study was obtained from
each patient.
2.2. Patients
A total 120 patients with CHB admitted to the university
hospital gastroenterology department between April 2009 and
December 2012 were included in this study. Patients presenting
directly to the gastroenterology department or referred from other
clinical centers to the department clinic as a tertiary healthcare
institution were recruited; they were included according to the
date at ﬁrst presentation to the department clinic. Inclusioncriteria were age 18 years, diagnosis with CHB infection (deﬁned
as positive HBsAg for more than 6 months), HBV DNA load 2000
IU/ml at least twice within the 6–12-month interval checks in the
past year, PNALT (according to at least four values obtained at 3-
month intervals in the past year), and no previous or concomitant
anti-HBV therapy. Patients with liver comorbidities including
hepatitis delta virus (HDV) infection, hepatitis C virus (HCV) co-
infection, chronic alcohol consumption (>30 g of pure alcohol per
day), Wilson’s disease, HIV co-infection, autoimmune hepatitis,
present or past evidence of any symptoms related to chronic liver
disease, and imaging or laboratory results that indicated cirrhosis
were excluded from the study, as were those with evidence of
immune suppression.
2.3. PNALT deﬁnition
PNALT was deﬁned according to the EASL guidelines; i.e., ALT
remaining below 40 IU/l when checked every 3–4 months within a
single year.8 Serum levels of ALT were measured every 3 months
for at least 1 year before liver biopsy.
2.4. Serum markers
All of the patients underwent serum biochemistry tests,
including for ALT, aspartate aminotransferase (AST), alkaline
phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin,
and alpha-fetoprotein, in addition to complete blood counts.
ELISAs were used to measure HBsAg, HBeAg, antibodies to HBeAg
(anti-HBe), antibodies to HCV (anti-HCV), HDV IgG antibodies
(anti-HDV), and HIV. Quantitative HBV DNA testing was performed
using the COBAS AmpliPrep/COBAS Taqman 96 system (Roche,
Branchburg, NJ, USA). The dynamic measurement level of the kit
ranges between 20 and 170 000 000 IU/ml.
2.5. Liver biopsy
All patients underwent a percutaneous liver biopsy guided by
ultrasonography. Liver biopsies were performed using 18-gauge
biopsy needles. The specimens obtained were ﬁxed, parafﬁn-
embedded, and stained with hematoxylin–eosin. Appropriate
diagnosis of a biopsy specimen included the observation of at
least six portal areas in the sample. To avoid differences and the
bias that can occur between examiners, all data were examined
and evaluated by a single experienced pathologist who was
blinded to the clinical data. Fibrosis and the HAI were scored using
the Ishak scoring system.11 Stages of ﬁbrosis ranged from 0 (no
ﬁbrosis) to 6 (cirrhosis; probable or deﬁnite).
2.6. Treatment indication
Treatment indication (signiﬁcant histological abnormalities)
was deﬁned as the presence of HAI 6 and/or the presence of stage
2 ﬁbrosis in liver biopsy specimens. The optimal age cut-off to
detect treatment indication was determined through receiver
operating characteristic (ROC) curve analysis. The optimal cut-off
point was calculated using the ROC curve coordinates for
treatment indication (point nearest to the top left corner, yielding
the best relationship between sensitivity and speciﬁcity).
2.7. Statistical analysis
NCSS (Number Cruncher Statistical System, 2007) and PASS
(Power Analysis and Sample Size, 2008) statistical software were
used for the statistical analysis (NCSS LLC, Kaysville, UT, USA).
Descriptive statistics such as the mean, standard deviation,
frequency, and rate were used. Furthermore, the Student t-test
Table 2
Histopathological ﬁndings in biopsy specimens of chronic
hepatitis B patients with persistently normal alanine
aminotransferase, according to the Ishak scoring system










HAI 6 or stage 2
Negative 72 (60.0%)
Positive 48 (40.0%)
HAI, histological activity index.
Table 3
Univariate analysis of factors associated with signiﬁcant necroinﬂammatory
A. Ormeci et al. / International Journal of Infectious Diseases 52 (2016) 68–7370was used to compare parameters with a normal spread between
the groups. Diagnostic screening tests and area under the ROC
curve (AUC) analysis were used to deﬁne the cut-off point for age.
The 95% conﬁdence intervals (CIs) were determined for all results;
p < 0.05 was considered signiﬁcant.
3. Results
A total 120 patients were included in the study, of whom 58
(48.3%) were male. The mean age of the patients was
42.88  11.32 years (range 20–72 years).
All patients were anti-HBe-positive with PNALT. None of the
patients were positive for anti-HCV or anti-HDV antibodies. All
patients underwent liver biopsies after 1 year of follow-up. The
mean HAI score was 2.89  2.30 (median 3, range 0–8), while the
mean stage was 1.1  0.95 (median 3, range 0–18) according to the
Ishak scoring system. The baseline demographic and laboratory
characteristics of the 120 patients are summarized in Table 1.
The histopathological ﬁndings on liver biopsy are shown in
Table 2. No patient had liver disease above stage 4. There were nine
patients (7.5%) with a HAI score of 6, seven (5.8%) with a HAI score
of 7, and two (1.7%) with a HAI score of 8; 40% of the patients had
HAI 6 or stage 2 disease, or both, which indicated treatment.
The HBV DNA load of all patients was above 2000 IU/ml at ﬁrst
examination and during the follow-up period. The mean HBV DNA
load was 123 680  494 500 IU/ml (5.09  5.69 log10 IU/ml). The
median HBV DNA value was 18 000 IU/ml (4.2, range 3.3–6.65 log10
IU/ml). With regard to viral load distribution, 68 patients (56.6%) had
an HBV DNA load in the range 2000–20 000 IU/ml and 43 (35.9%) had
an HBV DNA load in the range 20 000–200 000 IU/ml. Nine patients
(7.5%) had an HBV DNA load higher than 200 000 IU/ml.Table 1
Baseline demographic and laboratory characteristics of the 120 study
patients
Patients (N = 120)



















































ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, gamma-glutamyl transferase; HAI, histological
activity index; HBV, hepatitis B virus; SD, standard deviation.3.1. Analysis of factors associated with signiﬁcant necroinﬂammatory
activity and ﬁbrosis
The effect of each variable on signiﬁcant necroinﬂammatory
activity was assessed. Univariate analysis indicated that ALT, AST,
age, and male sex were associated with signiﬁcant necroinﬂam-
matory activity (HAI 6) in HBeAg-negative patients with PNALT
(Table 3). Moreover, age was associated with signiﬁcant ﬁbrosis in
these patients (Table 4).activity in HBeAg-negative patients with persistently normal alanine aminotrans-
ferase
Necroinﬂammatory activity p-Value
HAI <6 HAI 6
Age, years n = 102 n = 18
Mean  SD 41.86  11.29 48.67  9.98 0.018c*




AST, IU/l n = 102 n = 18
Mean  SD 22.64  5.86 25.83  6.63 0.038c*
Median (range) 22 (12–40) 25.5 (14–37)
ALT, IU/l n = 102 n = 18
Mean  SD 24.24  8.05 29.33  8.24 0.015c*
Median (range) 23 (11–40) 29.5 (12–40)
ALP, IU/l n = 102 n = 18
Mean  SD 123.53  55.48 145.62  51.4 0.076a
Median (range) 120 (46–332) 150 (34–210)
GGT, IU/l n = 102 n = 18
Mean  SD 22.51  15.57 23.5  9.14 0.261a
Median (range) 20 (7–131) 23 (8–48)
Total bilirubin, mg/dl n = 102 n = 18
Mean  SD 0.64  0.32 0.7  0.4 0.766a
Median (range) 0.6 (0–2.19) 0.67 (0.31–1.78)
Alpha-fetoprotein ng/ml n = 102 n = 18
Mean  SD 3.18  3.12 2.23  1.76 0.434a
Median (range) 2.2 (0.1–15) 1.95 (0.15–5)
Platelet count, 109/l n = 102 n = 18
Mean  SD 243.5  64.4 234.2  49.0 0.560c
Median (range) 233.5 (95–421) 226 (166–350)
HBV DNA, log10 IU/ml n = 102 n = 18
Mean  SD 5.13  5.72 4.72  5.03 0.763a
Median (range) 4.2 (3.3–6.6) 4.06 (3.34–5.64)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; GGT, gamma-glutamyl transferase; HAI, histological activity index;
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; SD, standard deviation.
aMann–Whitney U-test; bYates continuity correction test; cStudent t-test; *p < 0.05,
**p < 0.01.
Table 4
Univariate analysis of factors associated with signiﬁcant ﬁbrosis in HBeAg-negative
patients with persistently normal alanine aminotransferase
Stage p-Value
Stage <2 Stage 2
Age, years n = 77 n = 43
Mean  SD 41.25  10.68 45.81  11.98 0.034c*
Median (range) 41 (20–68) 47 (23–72)
Sex
Male 36 (46.8%) 22 (51.2%) 0.785b
Female 41 (53.2%) 21 (48.8%)
AST, IU/l n = 77 n = 43
Mean  SD 22.91  6.25 23.49  5.75 0.617c
Median (range) 22 (14–40) 23 (12–37)
ALT, IU/l n = 77 n = 43
Mean  SD 24.78  8.25 25.4  8.32 0.696c
Median (range) 24 (11–40) 24 (14–40)
ALP, IU/l n = 77 n = 43
Mean  SD 133.59  56.49 111.56  50.19 0.081a
Median (range) 120 (48–332) 110 (34–218)
GGT, IU/l n = 77 n = 43
Mean  SD 23.44  16.81 21.03  9.81 0.749a
Median (range) 20 (7–131) 20 (7–58)
Total bilirubin, mg/dl n = 77 n = 43
Mean  SD 0.66  0.34 0.61  0.31 0.384a
Median (range) 0.6 (0–2.19) 0.6 (0.2–1.78)
Alpha-fetoprotein, ng/ml n = 77 n = 43
Mean  SD 3.21  3.12 2.75  2.69 0.564a
Median (range) 2.2 (0.1–15) 2.05 (0.13–14)
Platelet count, 109/l n = 77 n = 43
Mean  SD 248.7  63.6 230.2  58.4 0.119c
Median (range) 239 (138–421) 230 (95–369)
HBV DNA, log10 IU/ml n = 77 n = 43
Mean  SD 5.16  7.75 4.92  5.53 0.164a
Median (range) 4.3 (3.3–6.6) 4.04 (3.3–6.3)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; GGT, gamma-glutamyl transferase; HAI, histological activity index;
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; SD, standard deviation.
aMann–Whitney U-test; bYates continuity correction test; cStudent t-test; *p < 0.05.
Table 5
Univariate analysis of factors associated with signiﬁcant ﬁbrosis and/or necroin-
ﬂammation in HBeAg-negative patients with persistently normal alanine amino-
transferase




Age, years n = 72 n = 48
Mean  SD 40.82  10.39 45.98  12.06 0.014c*
Median (range) 41 (20–64) 46.5 (23–72)
Sex
Male 34 (45.8) 24 (52.1) 0.628b
Female 39 (54.2) 23 (47.9)
AST, IU/l n = 72 n = 48
Mean  SD 23.08  6.16 23.17  5.96 0.942c
Median (range) 22 (14–40) 22 (12–37)
ALT, IU/l n = 72 n = 48
Mean  SD 24.88  8.20 25.19  8.40 0.840c
Median (range) 24 (11–40) 24 (12–40)
ALP, IU/l n = 72 n = 48
Mean  SD 132.77  56.88 115.74  51.39 0.130c
Median (range) 120 (48–332) 115 (34–218)
GGT, IU/l n = 72 n = 48
Mean  SD 23.29  17.06 21.58  10.38 0.971a
Median (range) 20 (7–131) 20 (7–58)
Total bilirubin, mg/dl n = 72 n = 48
Mean  SD 0.66  0.35 0.62  0.31 0.503a
Median (range) 0.6 (0–2.19) 0.6 (0.2–1.78)
Alpha-fetoprotein, ng/ml n = 72 n = 48
Mean  SD 3.28  3.22 2.72  2.60 0.509a
Median (range) 2.3 (0.1–15) 2 (0.13–14)
Platelet count, 109/l n = 72 n = 48
Mean  SD 250.8  65.2 229.08  55.5 0.060c
Median (range) 239.5 (138–421) 226 (95–369)
HBV DNA, log10 IU/ml n = 72 n = 48
Mean  SD 5.18  5.76 4.88  5.51 0.085a
Median (range) 4.30 (3.30–6.65) 4.01 (3.30–6.35)
HBV DNA, 3.30–4.30
vs. 4.30 log10 IU/ml
34 vs. 38 34 vs. 14 0.008a**
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate amino-
transferase; GGT, gamma-glutamyl transferase; HAI, histological activity index;
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; SD, standard deviation.
aMann–Whitney U-test; bYates continuity correction test; cStudent t-test; *p < 0.05,
**p < 0.01.
Table 6





























HBV, hepatitis B virus; HAI, histological activity index.
a HBV DNA 2000–20 000 IU/ml.
b HBV DNA 20 000 IU/ml.
*p < 0.05; **p < 0.01.
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signiﬁcant ﬁbrosis and/or necroinﬂammation
The effect of each variable on treatment indication was assessed
in HBeAg-negative patients with PNALT. When patients were
divided into two groups according to their viral load (2000–
20 000 IU/ml vs. 20 000 IU/ml), univariate analysis indicated that
age and HBV DNA viral load (2000–20 000 IU/ml) were associated
with signiﬁcant ﬁbrosis and/or necroinﬂammatory activity
(Table 5).
Histopathological ﬁndings and referral for treatment (HAI 6
and/or stage 2) according to the HBV DNA viral load group are
reported in Table 6. The results showed that an HBV DNA viral load
of 2000–20 000 IU/ml (odds ratio 3.098, 95% CI 1.228–7.814,
p = 0.017) and older age (odds ratio 1.055, 95% CI 1.010–1.103,
p = 0.017) were risk factors for requiring treatment (HAI 6 and/or
ﬁbrosis 2) on multivariate analysis (Table 7).
3.3. AUC for the association of age with treatment indication
Age was used to predict the probability of being diagnosed with
signiﬁcant histological abnormalities in HBeAg-negative patients
with PNALT. After assessment of the frequency of treatment
indication in all patients, the cut-off point for patient age was
determined to be 46 years and above. The AUC of the age associated
with requiring a treatment intervention in these patients was 0.71
(95% CI 0.580–0.847; sensitivity = 84.62%, speciﬁcity = 59.81%,
p = 0.012) (Figure 1).4. Discussion
In the present study, liver histology characteristics in HBeAg-
negative patients with PNALT and HBV DNA 2000 IU/ml, in
addition to risk factors for advanced ﬁbrosis and necroinﬂamma-
tory activity, were assessed.
HBV DNA viral load, ALT, and liver histology play important
roles in deﬁning the severity of liver disease in CHB patients.8 The
Table 7
Multivariate analysis for treatment indication
HAI 6 and/or stage 2 Multivariate analysis
OR 95% CI p-Value
Age, years 1.055 1.010–1.103 0.017*
Platelet count, 109/l 1.000 1.000–1.000 0.055
HBV DNA (3.30–4.30 log10 IU/ml)
a 3.098 1.228–7.814 0.017*
Sex, male 1.025 0.405–2.594 0.958
CI, conﬁdence interval; HAI, histological activity index; HBV, hepatitis B virus; OR,
odds ratio.
a HBV DNA = 2000–20 000 IU/ml.
*p < 0.05.
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and to identify patients who require treatment. However, ALT may
be inﬂuenced by various factors, making it an imperfect surrogate
marker.
EASL guidelines recommend non-invasive follow-up for liver
ﬁbrosis in PNALT patients with HBV DNA 2000 IU/ml with 3-
month ALT assessment intervals.8 Liver biopsy is not recom-
mended urgently, especially in PNALT patients with HBV DNA
levels between 2000 and 20 000 IU/ml. However, many studies
have reported signiﬁcant histological damage to the livers of
HBeAg-negative CHB patients with PNALT but high HBV DNA viral
loads.9,10,12,13 Kumar et al. detected stage 2 and above advanced
ﬁbrosis in over 40% of HBeAg-negative CHB patients with PNALT. 9
In the present study, the top ALT limit of 40 IU/l was used in
accordance with the EASL guidelines, yet stage 2 and above ﬁbrosis
was detected in 35.9% (n = 43) of patients; moreover, signiﬁcant
necroinﬂammatory (HAI 6) activity was detected in 15% (n = 18)
of patients. These data indicate that a sizable proportion of patients
with PNALT had developed signiﬁcant liver damage, as seen on
liver biopsy.
According to the EASL guidelines, high HBV DNA levels are a risk
factor for liver damage.8 HBV DNA is also a predictive factor for
hepatocellular carcinoma and cirrhosis.14–16 Papatheodoridis et al.Figure 1. Area under the curve (AUC) of age associated with treatment indication in
HBeAg-negative persistently normal ALT patients (AUC = 0.71, 95% CI 0.580–0.847;
sensitivity = 84.62%, speciﬁcity = 59.81%, p = 0.012).performed a systematic review and concluded that PNALT patients
with HBV DNA loads of 2000–20 000 IU/ml are indicated for ALT
assessment every 6 months, HBV DNA load measurement every
year, and follow-up with transient elastography and liver biopsy in
patients with elevated ALT levels.17 They suggest close follow-up
of patients who have HBV DNA loads of 2000–20 000 IU/ml.
Conversely, when patients were separated into two groups
according to their viral load (2000–20 000 IU/ml vs. 20 000 IU/
ml) in the present study, referral for treatment was signiﬁcantly
higher in the former group. An HBV DNA viral load of 2000–
20 000 IU/ml was determined to be a predictive factor for requiring
treatment intervention on univariate and multivariate analysis
(odds ratio 3.098, 95% CI 1.228–7.814, p = 0.017). It was also found
that histologically signiﬁcant liver disease is not rare in HBeAg-
negative patients with PNALT and with serum HBV DNA viral loads
of 2000–20 000 IU/ml. In patients infected later in life, CHB may be
indolent owing to immunoclearance; this results in HBeAg
seroconversion and a relatively low HBV DNA viral load.18,19
These are the patients in whom low HBV DNA loads with normal
ALT levels are likely (in those who are HBeAg-negative). As the
present data show, while this situation is complex, histologically
active liver disease can be suspected in patients with HBV DNA
viral loads of 2000–20 000 IU/ml. In order to assess the phase of
infection in CHB, serial HBV DNA and ALT measurements are
required, as the nature of CHB infection necessitates these tests.
Patients with HBV DNA levels between 2000 and 20 000 IU/ml and
normal ALT are considered to be within the ‘gray zone’. The follow-
up period in this group of patients is very important in order to
assess the phase of infection.
In this study, patients with HBV DNA values between 2000 and
20 000 IU/ml and with persistently normal aminotransferase
proﬁles were followed for 1 year. The short follow-up period might
a limitation of our study with regard to the deﬁnitI˙on of
persistently normal ALT. A longer follow-up period would be
beneﬁcial for understanding the aforementioned ‘gray zone’
patients.
The duration of disease is another factor eliciting liver damage.
Patients with PNALT who were infected perinatally have signiﬁ-
cantly worse liver damage than those infected in adulthood, since
the damage of ﬁbrosis increases with time. Patients who were
infected prenatally, during birth, or in their ﬁrst or second year of
life may have more extensive liver damage due to the fact that they
have a relatively longer immune-tolerance phase followed by an
equally prolonged immune-clearance phase.20–22 In the present
patient group, this translates into the probability that those with a
long disease duration may have signiﬁcant histological liver
damage.
Since HBV tends to exhibit a varying course, a single high HBV
DNA load at a single point in time is not sufﬁcient for an
appropriate assessment of the disease.7 In the present study, the
HBV DNA viral load was measured twice before liver biopsy, which
was performed 1 month after the last measurement. If any of the
HBV DNA viral load measurements were below 2000 IU/ml, that
patient was excluded from the study.
Age is also one of the most important factors that affect
histological activity and the stage of disease.23 All guidelines
recommend that patient age should be considered in making
treatment decisions, and patients over 40 years old (over 30 years
old according to the EASL; over 40 years old according to the
American Association for the Study of Liver Diseases and the Asian
Paciﬁc Association for the Study of the Liver) are currently
considered at risk.7,8,23 In the present study, age was used to
predict the probability of requiring treatment in HBeAg-negative
patients with PNALT. Following liver histopathology assessment,
the age cut-off was determined to be 46 years and over. Treatment
was indicated in 50% of patients older than 46 years and 33.3% of
A. Ormeci et al. / International Journal of Infectious Diseases 52 (2016) 68–73 73patients who were younger. The AUC of the age associated with
signiﬁcant liver histopathology in HBeAg-negative PNALT patients
was 0.71 (95% CI 0.580–0.847; sensitivity = 84.62%, speciﬁcity =
59.81%, p = 0.012).
A limitation of the present study is that the patients’ HBV
genotypes were not investigated, since HBV genotyping is not
routinely performed in clinical practice.
In this cohort, treatment necessity in the HBeAg-negative
CHB infection patients with HBV DNA levels between 2000 and
20 000 IU/ml was signiﬁcantly greater than found in previous
studies in the literature. As mentioned before, longer and
more detailed follow-up of these ‘gray zone’ patients, or re-
evaluation of the patients with non-invasive methods (such as
the AST-to-platelet ratio index (APRI), ﬁbrosis 4 score, FibroTest,
and vibration-controlled transient elastography), is recom-
mended.
In conclusion, signiﬁcant liver damage requiring treatment was
detected in 40% of CHB patients with PNALT and a high HBV DNA
load (2000 IU/ml) after undergoing liver biopsy. Furthermore,
HBeAg-negative CHB patients with PNALT do not have a benign
prognosis, and patients with an HBV DNA viral load of 2000–
20 000 IU/ml who are 46 years old are more likely to be
candidates for treatment.
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